The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Methotrexate + infliximab showed no clear difference in failure to enter remission at 14 weeks or 24 weeks (Feagan 2014) compared with infliximab alone (low certainty).
It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
Methotrexate + infliximab showed no clear difference in withdrawals due to adverse event (Feagan 2014) compared with infliximab alone (low certainty).
Methotrexate + infliximab showed no clear difference in proportion of patients maintaining remission compared with infliximab +/‐ placebo (low certainty).
It is very uncertain whether methotrexate + sulfasalazine changes maintenance of Remission compared with sulfasalazine (very low certainty).
Rituximab (2 x 1000 mg) plus methotrexate probably leads to higher clinical improvement American College of Rheumatology 50%… compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in clinical remission (Disease Activity Score‐28 joint count < 2.6)… compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate leads to higher physical function (HAQ‐DI MCID = ‐0.22) Analysis 1.10 compared with methotrexate monotherapy (high certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in no radiographic progression in total Genant‐modified Sharp score… compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate leads to higher health‐related quality of life compared with methotrexate monotherapy (high certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).